Document is current
Any future updates will be listed below
-
Authors
Einarsdottir, Sigrun https://orcid.org/0000-0003-4756-6805
Lobaugh, Stephanie
Luan, Danny
Gomez-Llobell, Marina
Subramanian, Padmapriya
Devlin, Sean https://orcid.org/0000-0002-6801-720X
Chung, David
Dahi, Parastoo B. https://orcid.org/0000-0002-0794-3226
Falchi, Lorenzo https://orcid.org/0000-0003-1531-3838
Giralt, Sergio https://orcid.org/0000-0003-1944-5053
Landau, Heather https://orcid.org/0000-0002-3152-1189
Lesokhin, Alexander M. https://orcid.org/0000-0001-9321-702X
Lin, Richard https://orcid.org/0000-0002-0834-7880
Lue, Jennifer https://orcid.org/0000-0001-8153-1820
Mailankody, Sham https://orcid.org/0000-0002-2815-9561
Palomba, M. Lia https://orcid.org/0000-0001-5099-9156
Park, Jae H. https://orcid.org/0000-0002-2903-5130
Salles, Gilles https://orcid.org/0000-0002-9541-8666
Scordo, Michael
Escribano-Serrat, Silvia
Sanz, Jaime
Rejeski, Kai https://orcid.org/0000-0003-3905-0251
Shouval, Roni https://orcid.org/0000-0001-9827-8032
Usmani, Saad https://orcid.org/0000-0002-5484-8731
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
Shah, Gunjan https://orcid.org/0000-0002-9977-0456
Shahid, Zainab https://orcid.org/0000-0002-6664-8243
- License Information
-
More Information
Article History
Received: 13 March 2025
Revised: 19 May 2025
Accepted: 17 June 2025
First Online: 2 July 2025
Competing interests
: Stephanie Lobaugh, Padmapriya Supramanian, Sean Devlin, Parastoo Dahi, Alexander Lesokhin, Maria Palomba, Gilles Salles, Lorenzo Falchi, Heather Landau, Jae Park, Sham Mailankody - Nothing to Declare. Sigrun Einarsdottir: research funding (institutional) from MSD. Michael Scordo served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, Amgen Inc., Bristol Myers Squibb, and Sanofi; served on ad hoc advisory boards for Kite – A Gilead Company, and Miltenyi Biotec; and received honoraria from i3Health, Medscape, CancerNetwork, and IDEOlogy. Gunjan Shah: research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, GPCR, and Recordati, and is on the DSMB for ArcellX. Dr. Perales reports honoraria from Adicet, Allogene, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, Takeda, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. Roni Shouval reports speaker honoraria from Incyte and Sanofi. Kai Rejeski: Kite/Gilead: Research funding, Consultancy, Honoraria and travel support; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre; travel support. CSL Baehring: Consultancy. Saad Usmani: Research funding (past 2 years): Abbvie, BMS/Celgene, GSK, Gilead, Gracell Biotechnologies, Janssen. Consulting (past 2 years): Abbvie, BMS/Celgene, Genentech, Gilead, GSK, Janssen, Kite/Arcellx, Oricell Therapeutics, Pfizer, Regeneron, Sanofi. Sergio Giralt: Research Funding: Amgen, J&J, Takeda, Celgene, Actinuum, Sanofi, Miltenyi, Kite, EUSA. Consultancy: Amgen, J&J, Takeda, Celgene, Actinuum, Sanofi. Miltenyi, Novartis, Kite, Novartis, Jazz, BMS, Crisper, EUSA Omeros.
: All methods were performed in accordance with relevant guidelines and regulations. Approval from Institutional Review Board (IRB)/Privacy Board at Memorial Sloan Kettering Cancer Center (MSK) was obtained, reference number: 23-070. Informed consent was waived by the Ethics committee due to the retrospective nature of the study and minimal risk to participants.
